PHYSIOLOGIC LONG-ACTING BASAL INSULIN, INTERACTIVE (ARS) CASE MANGEMEMENT SESSION #1 — Applying Updated ADA/EASD Guidelines to a Patient with T2D Who Has Not Achieved Ideal HA1c Levels with Metformin plus an SGLT-2 Inhibitor and Who is at Moderate to Significant Risk for Hypoglycemia

Related Videos

Interactive Q&A Session and Special “Hot Topics in T2D” Session “Hot Topics” in Type 2 Diabetes: Focus on Physiologic Basal Insulin and Combination Regimens

The Current and Future Roadmap to Optimizing Basal Insulin-Based Glycemic Control in T2D The Foundational Role of Long-Acting Basal Insulin in the PCP’s Anti-Diabetic Toolkit: Evidence-, Guideline, and Mechanism-Based Strategies for Improving the Safety (Risk of Hypoglycemia) and Efficacy Equation for Insulin-Based Glycemic Control A Practical Roadmap for the Front Lines of Primary Care and Internal Medicine Specialty Practice: Risk Stratification Tools for Recognizing and Preventing Hypoglycemia

PHYSIOLOGIC, BASAL INSULIN, INTERACTIVE (ARS) CASE MANGEMEMENT SESSION # 3: Presentations, interactive discussion, and evaluation of two patients who have been on various insulin formulations — including NPH and basal insulin and with drug administration and dosing issues—who present with specific clinical profiles, safety needs, and glycemic dysregulation issues that make them ideal candidates for a long-acting physiologic insulin and for switching from one kind of insulin regimen to another.

Practical Aspects of Switching to a Physiologic, Basal Insulin Formulation: Targeting Diabetic Patients Who Should be Initiated on or Switched to a Long-Acting, Physiologic Insulin — How to Switch? Patient Information-Sharing, Dosing Considerations, and Improving Regimen Adherence and Safety Through Improved Insulin-Delivery Devices and Patient Education

PHYSIOLOGIC, BASAL INSULIN, INTERACTIVE (ARS) CASE MANGEMEMENT SESSION #2— Optimizing Glycemic Control in the Vulnerable, Poorly Compliant, and/or Elderly Patient with T2D at Risk for Hypoglycemia: What is the Mechanistic Rationale for Early Initiation of a Physiologic, Basal Insulin in Vulnerable Patients Who Require Intensified Glycemic Control?

All Basal Insulins Are Not Created Equal: Comparative PK/PD, Efficacy, Side Effect (Nocturnal Hypoglycemia), and Safety Profiles for Established and New, Longer-Acting Basal Insulins: An Evidence- and Trial-Based Translational Roadmap for the Primary Care and Internal Medicine Specialist

Optimizing Glycemic Control While Mitigating Hypoglycemic Risk in T2D: Why, When, and in Whom Do ADA/EASD Guidelines Recommend “Physiologic” Basal Insulin for T2D? Expert- and Trial-Based Evidence for the Safety and Efficacy of Long-Acting Basal Insulin

Basal Insulin as a Foundational Strategy in T2D: The Evidence-Based Rationale for Optimizing HA1c Target Goal Attainment with Physiologic, Long-Acting Basal Insulin: Patient Targeting, Switching and Sequencing Strategies